IOVANCE BIOTHERAPEUTICS, INC. cotiza a 14.27 USD y tiene una capitalización bursátil de $6.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individua…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.19 | $-0.18 |
| Estimado | $-0.09 | $-0.13 | $-0.15 | $-0.18 |
| Sorpresa | — | +15.4% | -26.7% | +0.0% |
| Métrica | IOVA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 34.3% | 57.0% | -22.8% |
| Operating Margin | -153.1% | -38.6% | -114.5% |
| Net Margin | -148.4% | -33.6% | -114.8% |
| FCF Margin | -127.6% | -13.9% | -113.8% |
| ROE | -56.0% | -40.4% | -15.6% |
| ROA | -42.8% | -32.0% | -10.8% |
| Current Ratio | 3.20 | 2.84 | +0.36 |
| Debt / Equity | — | 0.28 | — |